Summary Congress 2014

Summary Congress 2016

Eventos relacionados

Visit Counter

0620190
Today
Yesterday
This Week
Last Week
This Month
Last Month
All
78
91
1601
522852
2982
4806
620190

Photos of the 2016 UPD Congress with the treatment of Heberprot-P

 

 

 

Congress 2018

International Congress Workshop on Practical Application of human recombinant Epidermal Growth Factor (hrEGF) in Patients with Diabetic Foot Ulcer

Date: December, 2018
To be held at Melia Habana Hotel, Cuba

Main topics

  • Main elements of the healing mechanism in diabetic patients.
  • Role of human recombinant Epidermal Growth Factor (hrEGF) in wound healing.
  • Development and main achievements of Heberprot-P therapy.
  • Practical Procedures backed up by the Cuban Health Ministry for the comprehensive care of diabetic foot ulcers.
  • Diabetic foot ulcer classification used in Cuba.
  • Practical procedures in the treatment of neuropathic diabetic foot ulcers.
  • Practical procedures in the treatment of ischemic diabetic foot ulcers.
  • Most frequent reported adverse events using Heberprot-P.
  • Practical experiences in the treatment of very complex diabetic foot ulcers.

International Congress: Controlling diabetes and its more severe complications

Date: December 2018.
To be held at: Memories Varadero Hotel, Varadero, Matanzas, Cuba

Endorse this conclave:

  • Cuban Society of Diabetes.
  • Cuban Society of Endocrinology.
  • Cuban Society of Angiology and Vascular Surgery.
  • Center for Genetic Engineering and Biotechnology.
  • HeberBiotec SA.

 

Main topics

  • Diabetes prevention.
  • Diabetes as metabolic .
  • Links between obesity and diabetes.
  • Diabetes type 1 and 2. Global medical updates in early detection, metabolic control and treatments.
  • Gestational Diabetes.
  • Retinopathy, nephropathy and neuropathy produced by diabetes.
  • Incretine system and cardiovascular protection.
  • Diabetes control through insulin. State of the art in insulinization.
  • Molecular biology of wound healing mechanisms.
  • Failure of healing mechanisms in diabetic patients.
  • Role of different growth factors in regulating wound healing mechanisms.
  • Diabetic foot ulcer as a severe diabetes complication.
  • Could be considered the local infiltration of human recombinant growth factor (hrEGF) (Heberprot-P) the first and unique replacement therapy in the treatment of diabetic foot ulcers?
  • Practical procedures in the treatment of infected diabetic foot ulcer.
  • Peripheral arterial disease.
  • Revascularization procedures.
  • Neuropathic and ischemic diabetic foot ulcer patients, main differences and similarities among them.
  • Charcot foot.
  • Main achievement and challenges in the state of the art of diabetic foot ulcer treatments.
  • Practical medical experiences in the use of human recombinant epidermal growth factor in the treatment of very complex diabetic foot ulcers.
  • Implementation of health programs to control diabetes.
  • Active surveillance for early detection of diabetic foot ulcers.
  • Role of primary, secondary and tertiary health care levels in the implementation of comprehensive care programs for diabetic foot ulcer patients.
  • Comprehensive care program to guarantee safe pregnancy in diabetic women.
  • New development in the control of diabetes.
  • Post marketing pharmaco-vigilance of Heberprot-P in the Cuban health system.
  • Biosafety record of the use of human recombinant epidermal growth factor in diabetic foot ulcer patients.